



Government of the District of Columbia Department of Health

Prescription Drug Monitoring Program
Advisory Committee Meeting

899 NORTH CAPITOL ST. NE - 2ND FLR. WASHINGTON, DC 20002

WebEx Virtual MEETING

August 15, 2023 10 AM—12:00 PM

AGENDA

CALL TO ORDER: 10:02 am

PRESIDING: Jacqueline Watson, DO, MBA Chairperson

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY COMMITTEE MEMBERS:			
	Jacqueline Watson, DO, MBA, DC Health Chief of Staff	Present	
	Justin Ortique, PharmD, RPh, CPM, Board of Pharmacy Executive Director	Present	
	Sithembile Chithenga, MD, MPH, Board of Medicine Executive Director	Absent but represented by Suzanne Fenzel	
	Vito DelVento, DVM, MS, Board of Veterinary Medicine Executive Director	Present (Joined at 10:1 1am)	
	Teresa Walsh, PhD, RN, NE-C Board of Nursing Executive Director	Present (Joined at 10:25 am)	
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	Present	
	Sheri Doyle, MPH, Consumer Member	Present	
	Captain Shawn Rooney, Metropolitan Police Department	Absent but represented by Captain Porter	
	Lakisha Stiles, CPhT, Pharmacy Technician	Absent	
	Careen-Joan Franklin, PharmD, RPh, Pharmacist	Present	
PDMP STAFF:	Reginal Bellamy, PharmD, RPh, Supervisory Pharmacist	Present	
	Uche Ekwomadu, MPH, MPharm, Public Health Analyst	Present	
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP Attorney Advisor	Present	
VISITORS:	Orlando Baker, Department of Behavioral Health (DBH)		
	Lauren Keifer Account Specialist, Bamboo Health		
	Kimberly Brown, Mayor's Office of Ethics and Accountability		
	Justin Wood, Drug Enforcement Agency (DEA)		
	Claire Bonaci, Bamboo Health		

Open Session Agenda

Quorum: Yes

0815-O-01	Welcome & Introductions Chair	Dr. Watson
	<u>Report</u>	
	Charge of the Committee	
	The Committee shall convene at least two (2) times per year to advise the Director:	
	(a) On the implementation and evaluation of the Program;	
	(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;	
	(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;	
	(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regardingthe indications of possible abuse or misuse of coveredsubstances;	
	(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and	
	(f) Regarding the design and implementation of educational coursesfor:	
	(1) Persons who are authorized to access the prescription monitoring information;	
	(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;	
	(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and	
	(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	
	The Committee Chair welcomed everyone and began roll call of all Committee members, staff and the public attending the committee meeting.	
0815-O-02	Approval of April 2023 PDMP Advisory Committee Meeting Minutes	
	(a) Minutes from the April 2023 Meeting	
	Motion: Dr. Careen-Joan Franklin made the motion to approve the April 2023	

	meeting minutes.	
	Seconded by: Committee Member, Dr. Justin Ortique.	
	Roll Call Vote:	
	Dr. Vito DelVento : Voted in favor of the motion.	
	Dr. Natalie Kirilichin: Voted in favor of the motion.	
	Dr. Careen-Joan Franklin: Voted in favor of the motion.	
	Dr. Justin Ortique: Voted in favor of the motion.	
	Captain Porter: Voted in favor of the motion.	
	Abstentions: Suzanne Fenzel.	
	Motion Carried	
0815-O-03	Welcome of the new committee members	
	The Committee Chair welcomed the three new Committee members and indicated	
	that more members will be added before the next advisory committee meeting.	

Ns. Williams PDMP Legislative Update Ms. Carla Williams gave the update on the pending PDMP legislation that expanded the authority of the Director of the Department of Health to provide PDMP related information and charge a fee to offset operational costs. The Bill was introduced to DC Council in April and a hearing was held in July. We are currently awaiting any further council action.

0815-O-05 Program Updates

Dr. Ortique

(a) PDMP Registration Statistics and Compliance			
Licensed Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Pro fessionals Registered with the PDMP
Physician	13,988	12,710	90.9%
Physician Assistant	1,119	1,034	92.4%
Advanced Practice Nurse	3,909	3,168	81.2%
Pharmacist	2,065	1,981	96.0%
Dentist	1,317	1,136	86.3%
Veterinarian	498	448	90%
Podiatrist	152	146	96%
Optometrist	224	212	94.6%
Naturopathic Physician	61	49	80.3%
VA Prescriber		285	
VA Dispenser		42	
Pharmacy Technician or Delegate	1,029	4	0.39%
Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		33	
Total	24,362	18,775	89.5%

*Current as of 08/4/2023

(b) Outreach Activity

Outreach activities since the April 2023 meeting:

Date of Event	Name of Event	Type of Event	Topics Discussed		Number of Participants
5/18/23	Opioid Use Disorder Treatment Integrated with Primary Care	CE webinar	DACS	DC prescribers and dispensers	218
8/8/23	Opioid Fatality Review Board (OFRB) Presentation	Presentation	DC PDMP	OFRB Members and Stakeholders	~24

Executive Director for the Board of Pharmacy gave an update on PDMP Registration compliance. The Committee Chair reminded the committee of our agreement from our April 2023 meeting about disciplinary actions and fines and added that our actions be consistent across boards.

Dr. Walsh added that a fine of \$500 was established, as well as a negotiated settlement agreement. Dr. Watson then reiterated the importance of ensuring compliance before the end of the fiscal year.

Executive Director for the Board of Pharmacy provided PDMP program updates related to outreach activity in May, "Opioid Use Disorder Treatment Integrated with Primary Care," delivered through the District Addiction Consultation Service, with 218 participants. He also gave a presentation at the Opioid Fatality Review Board.

0815-O-06

Grant Updates

Dr. Ortique

(a) Districtwide Gateway Integration

A total of 96 health entities have connected to the DC PDMP through Gateway Integration in total since integration began in 2019.

(b) District Addiction Consultation Services

Launched July 2021

https://www.medschool.umaryland.edu/dacs/

District Addiction Consultation Services is a resource for providers. It is a substance use warm line operated Mon-Fri 9-5. Callers can ask general questions about behavioral health resources and referrals.

Clinical questions are forwarded to a certified physician consultant who will return the call within 24 hours.

PDMP staff members have collaborated with DACS staff to create an informational presentation on the program.

As of March 17th, 1,201 practitioners enrolled in DACS, and the program has received 90 consultation calls.

DC PDMP staff plan to collaborate with DACS staff to host additional webinars, develop outreach materials, and prepare to launch a monthly newsletter.

(c) Opioid Communications Campaign

My Recovery DC
Ads began running in July 2021
https://myrecoverydc.org/

Many of the bus wraps, bus shelter ads, and interior bus cards have continued to run to date, at no additional cost to DC Health.

Dr. Ortique

Engage Strategies is currently in the process of revamping the campaign with new interviews and new promotional materials underway.

The Executive Director for the Board of Pharmacy provided an update on recent program efforts in the promotion of districtwide PMP Gateway integration, and it was noted that 96 health entities have connected to the DC PDMP through PMP Gateway integration since efforts began in 2019.

An update was given that the opioid communication campaign has relaunched and is currently under way.

0815-0-07

Presentation

DC Prescription Drug Monitoring Program - Program Updates(attached)
Justin Ortique, PharmD, RPh, CPM Executive Director/Program Manager, HRLA

The Executive Director did the presentation for the Board of Pharmacy, Dr. Ortique. The presentation started with the vision and mission of DC Health. The strategic priorities of DC Health were equally stated. The Executive Director Board of Pharmacy presented the DC Health PDMP timeline from 2012 when the stakeholder drafted the PDMP legislation to the present date. It was noted that a standard operating procedure is currently in place to ensure compliance with the DC PDMP. He noted a significant increase in compliance within the Board of Veterinary Medicine with a 27 percent increase in registration. It was also noted that the number of Advisory Committee members was increased to 13, and the new members (once appointed) will attend our next meeting. The committee was informed that our gateway communication campaign will be ending soon. Furthermore Dr. Ortique expanded upon the OFRB Presentation and that was provided. The OFRB requested additional information from the PDMP Program in regard to OTPs and reporting to the PDMP. The information will be researched and provided to the OFRB at a later date.

Dr. Franklin asked about the PDMP's approach to dealing with prescriber report that shows a suspicious prescribing pattern. She also asked if the PDMP is supposed to be made aware of poor prescribing practices. Dr. Ortique responded that the prescriber report is mainly for self-assessment and that the PDMP does not look at that; also, the PDMP gets involved based on complaints. Dr. Franklin added that those reports could support DEA action in addition to providing insights for prescribers. Carla Williams added that the committee does not have any regulatory authority over prescribers and that we can only make recommendations to the Director of the Department of Health. Furthermore, she reminded members of the charge of the committee.

The Executive Director for the Board of Nursing added that in the future, she is open to strategizing on ways to assist nurses with substance abuse problems in aetting treatment.

899 North Capitol Street NE | 2nd Fl, Washington, DC 20002 | E doh.pdmp@dc.gov | https://dchealth.dc.qov/pdmp

0815-O-08	Action Items	Dr. Ortique/
	Potential Future meeting date	Dr. Watson
Matters for		
Consideration	January 9, 2024, from 10 am to 11:30 am, was selected as the date and time for	
	the next Advisory Committee meeting, which will be in person.	
	The Committee Chair also tasked the program also further review the	
	charge of the committee and comeback with potential	
	recommendations on the establishment of criteria for indicators of possible misuse or abuse of covered substances; as well as	
	standardization of the methodology that should be used for analysis	
	and interpretation of prescription monitoring data.	
0915 0 00		
0815-O-09	Other news/highlights from Committee members	
	Captain Porter added that there had been a lot of synthetic amphetamine on the	
	streets. He added that they are seeing decreased pharmacy robbery, especially	
	for pharmacies with specialized security systems.	
	Dr. DelVento added that the new licensing requirement by the DEA does not	
	apply to Veterinarians.	
Comments from th	e No comments from the public	
Motion to Adjourn the	Motion : Dr. Ortique made the motion that the Committee close the meeting.	
Open Session	Seconded by: Committee Member, Dr. Natalie Kirilichin.	
	Roll Call Vote:	
	Dr. Vito DelVento : Voted in favor of the motion.	
	Dr. Natalie Kirilichin: Voted in favor of the motion.	
	Dr. Careen-Joan Franklin: Voted in favor of the motion.	
	Dr. Justin Ortique: Voted in favor of the motion.	
	Captain Porter: Voted in favor of the motion.	
	Dr. Theresa Walsh: Voted in favor of the motion.	
	Sheri Doyle: Voted in favor of the motion.	
	Suzanne Fenzel: Voted in favor of the motion.	
	Abstentions: None	
	Motion Carried	
	(Roll Call Vote)	
This concludes the		

This concludes the meeting.

Meeting Adjourned at 11:27 am

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.